Moreover, AXL overexpression was observed in 20% of NSCLC patients with resistance to EGFR inhibitors; in other cancers, enhanced AXL expression was also involved in intrinsic or acquired resistance to PI3K inhibitors, anti-HER2 treatment, immune checkpoint inhibitors in addition to chemotherapy and radiotherapy [19–22]. The gene discussed is EGFR; the disease is cancer.